Venus Remedies gets US patent for its new antibiotic product

Venus Remedies Limited, a research based global pharmaceutical company, has received patent from the US Patent Office for a breakthrough antibiotic product.

• The new drug product CSE1034 which is an antibiotic adjuvant entity (AAE), has been found to be effective against a wide range of drug resistant infections including the `superbugs’ like carbapenemase resistant Metallobetalactamses (MBL) strains, the company announced.
• Venus’ drug has a unique profile of action which gives it an edge over all the existing therapies. “This unique antibiotics adjuvant entity creates a synergistic effect due to its activity on AMRINGER (Acquired Multiple Resistance in Gram Negative Enterococci and Rods) which stops development and spread of bacterial resistance. Experience with clinical studies on more than 1000 patients have indicated approximately 20-30 per cent reduction in cost of therapy compared to conventional therapies being used

Venus Remedies is planning to launch this drug in India under the brand name ELORES and is planning to have a pre IND meeting with US FDA for fast track approval of this product.
http://pharmabiz.com/NewsDetails.aspx?aid=69513&sid=2